Overview

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal
Sorafenib